Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 114, Issue 13, Pages E2563-E2570Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1621513114
Keywords
nuclear receptors; drug discovery; structure-based design; peroxisome roliferator-activated receptor; cation-pi interaction
Categories
Funding
- National Science Foundation [EEC-0813570]
- NIH [DK057978, HL105278, DK090962, HL088093, ES010337, CA014195]
- Leona M. and Harry B. Helmsley Charitable Trust [2012-PG-MED-002]
Ask authors/readers for more resources
The peroxisome proliferator-activated receptor (PPAR) family comprises three subtypes: PPAR alpha, PPAR gamma, and PPAR delta. PPAR delta transcriptionally modulates lipid metabolism and the control of energy homeostasis; therefore, PPAR delta agonists are promising agents for treating a variety of metabolic disorders. In the present study, we develop a panel of rationally designed PPAR delta agonists. The modularmotif affords efficient syntheses using building blocks optimized for interactions with subtype-specific residues in the PPARd ligand-binding domain (LBD). A combination of atomic-resolution protein X-ray crystallographic structures, ligand-dependent LBD stabilization assays, and cell-based transactivation measurements delineate structure-activity relationships (SARs) for PPAR delta-selective targeting and structural modulation. We identify key ligand-induced conformational transitions of a conserved tryptophan side chain in the LBD that trigger reorganization of the H2'-H3 surface segment of PPARd. The subtype-specific conservation of H2'-H3 sequences suggests that this architectural remodeling constitutes a previously unrecognized conformational switch accompanying ligand-dependent PPAR delta transcriptional regulation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available